Neurotrope (NTRP) Upgraded at ValuEngine

ValuEngine upgraded shares of Neurotrope (NASDAQ:NTRP) from a hold rating to a buy rating in a report published on Tuesday morning.

Other equities research analysts have also issued research reports about the company. Maxim Group began coverage on Neurotrope in a research report on Wednesday, May 16th. They issued a buy rating and a $16.00 price target on the stock. Zacks Investment Research downgraded Neurotrope from a hold rating to a sell rating in a research note on Friday, May 11th. Finally, Roth Capital began coverage on Neurotrope in a research note on Thursday, March 8th. They issued a buy rating and a $15.00 price objective on the stock.

Neurotrope opened at $9.59 on Tuesday, according to Marketbeat. Neurotrope has a 12 month low of $3.40 and a 12 month high of $9.94.

An institutional investor recently raised its position in Neurotrope stock. Tanaka Capital Management Inc. grew its holdings in Neurotrope (NASDAQ:NTRP) by 59.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 128,310 shares of the company’s stock after purchasing an additional 47,605 shares during the quarter. Neurotrope comprises about 2.1% of Tanaka Capital Management Inc.’s portfolio, making the stock its 16th biggest position. Tanaka Capital Management Inc. owned approximately 1.62% of Neurotrope worth $903,000 at the end of the most recent quarter. Institutional investors and hedge funds own 14.46% of the company’s stock.

Neurotrope Company Profile

Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease (AD). Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with's FREE daily email newsletter.

Leave a Reply